Description: Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Home Page: www.cogrx.com
CGTX Technical Analysis
2500 Westchester Avenue
Purchase,
NY
10577
United States
Phone:
412 481 2210
Officers
| Name | Title |
|---|---|
| Ms. Lisa Ricciardi | CEO, Pres & Director |
| Dr. Anthony O. Caggiano M.D., Ph.D. | Chief Medical Officer and Head of R&D |
| Mr. Andrew J. Einhorn CPA | Interim Chief Financial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9673 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-10-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 19 |